(via TheNewswire)

Vancouver, British Columbia, March 10, 2026 – TheNewswire — Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today that Joshua Bartch has resigned as director, president and chief executive officer of the Company.

The Company has appointed Jason Birmingham, who was previously appointed chief strategy officer on February 2, 2026, to assume all three positions formerly held by Mr. Bartch.

The Company would like to thank Mr. Bartch for his service and wishes him well in all his future endeavors.

NOVERIS HEALTH SCIENCES INC.

Jason Birmingham

Chief Executive Officer  

Email: jason0612@gmail.com

Phone: +1 (888) 871 - 3936

About Noveris Health Sciences Inc.  

The Company is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Noveris’ dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the Company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Noveris’ approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with worldclass scientific and regulatory expertise.  

NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Copyright (c) 2026 TheNewswire - All rights reserved.